AbbVie’s Etentamig Delivers Positive Phase III CERVINO Results in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
AbbVie (NYSE: ABBV) announced positive topline results from the Phase III CERVINO study evaluating etentamig,...
NYSE: ABBV
Allergan Aesthetics’ SKINVIVE by Juvéderm Wins NMPA Approval for Perioral Wrinkles, Backed by 93.4% POLSS Responder Rate
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced that its SKINVIVE by Juvéderm, an injectable...
AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn’s Disease
AbbVie (NYSE: ABBV) announced that it has submitted an application to the European Medicines Agency...
Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), announced that the U.S. Food and Drug...
AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance
AbbVie (NYSE: ABBV) announced financial results for the second quarter (Q2) of 2026. Financial Performance...
Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed/Refractory DLBCL
Genmab A/S (NASDAQ: GMAB) and AbbVie Inc. (NYSE: ABBV) announced on July 23, 2026 that...
Allergan Aesthetics Secures European Commission Approval for Boey (trenibotulinumtoxinE) – First Rapid-Onset, Short-Duration Botulinum Neurotoxin Serotype E for Glabellar Lines
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that the European Commission has approved Boey...
AbbVie Secures European Commission Approval for TEPKINLY Combination Therapy in Relapsed/Refractory Follicular Lymphoma with 79% Reduction in Disease Progression Risk
AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for...
AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx
AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, demonstrating...
AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older
AbbVie (NYSE: ABBV) announced on June 26, 2026, that the U.S. Food and Drug Administration...
AbbVie’s SKYRIZI (Risankizumab) Secures European Commission Approval for Pediatric Plaque Psoriasis – First IL-23 Inhibitor Authorized for Children as Young as Six
AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for...
AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline
AbbVie Inc. (NYSE: ABBV) and Apogee Therapeutics, Inc. (NASDAQ: APGE) announced a definitive agreement for...
AbbVie’s AQUIPTA (Atogepant) Receives European Commission Approval for Acute Migraine Treatment, Expanding Beyond Preventive Use
AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for...
AbbVie’s VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment
AbbVie (NYSE: ABBV) announced that the European Commission (EC) has granted an expanded marketing authorization...
AbbVie Secures FDA Approval for DECNUPAZ in Blastic Plasmacytoid Dendritic Cell Neoplasm – First CD123-Targeting ADC Addresses Ultra-Rare Hematologic Malignancy
AbbVie Inc. (NYSE: ABBV) announced on May 27, 2026, that the U.S. Food and Drug...
AbbVie Secures CHMP Positive Opinion for MAVIRET in Acute Hepatitis C Treatment Across All Age Groups
AbbVie Inc. (NYSE: ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP)...
Allergan Aesthetics Secures CHMP Positive Opinion for Boey (TrenibotulinumtoxinE) in Glabellar Lines Treatment Across European Economic Area
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that the European Medicines Agency’s (EMA) Committee...
Allergan Aesthetics Secures First-in-China NMPA Approval for Juvéderm VOLUMA Temple Indication
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced it has received marketing approval from China’s...
AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength
AbbVie Inc. (NYSE: ABBV) reported first quarter 2026 financial results with worldwide net revenues of...
AbbVie Submits FDA Application for RINVOQ in Severe Alopecia Areata – Expanding JAK Inhibitor Franchise
AbbVie Inc. (NYSE: ABBV) announced the submission of a supplemental New Drug Application (sNDA) to...